Montelukast Use in a 10-Month-Old Infant

Montelukast can be given to a 10-month-old infant for perennial allergic rhinitis, as the FDA has approved montelukast 4-mg oral granules for children as young as 6 months of age for this indication. 1

However, montelukast is NOT FDA-approved for asthma treatment in infants younger than 12 months of age. 1

FDA-Approved Indications by Age

For Perennial Allergic Rhinitis:

Montelukast 4-mg oral granules are FDA-approved for children 6 months to 14 years of age 1
At 10 months of age, your patient falls within this approved age range for allergic rhinitis treatment 1

For Asthma:

Safety and effectiveness have NOT been established in pediatric patients younger than 12 months of age with asthma 1
FDA approval for asthma begins at 12 months of age 1

Dosing for a 10-Month-Old

The appropriate dose is montelukast 4-mg oral granules administered once daily 1, 2

This formulation can be administered directly in the mouth, dissolved in 1 teaspoon of baby formula or breast milk, or mixed with a spoonful of soft food 1
The granules should not be opened until ready for use 1

Critical Safety Considerations

FDA Black Box Warning (2020):

The FDA issued a black box warning regarding serious neuropsychiatric events with montelukast, including suicidal thoughts and actions, depression, anxiety, sleep disturbances, and behavioral changes 3, 4, 5

Before prescribing montelukast to any child, you must:

Explicitly discuss neuropsychiatric risks with parents, including the potential for behavioral changes 4, 5
Consider whether safer alternatives (such as intranasal corticosteroids for allergic rhinitis) are appropriate 4, 5
Recognize that the FDA explicitly states montelukast's benefits may not outweigh risks, especially for mild disease 4, 5

Monitoring Requirements:

Monitor for unusual behavioral or mood changes, particularly in the first weeks of therapy 4, 5
Do not continue therapy without reassessing risk-benefit if any neuropsychiatric symptoms emerge, even if mild 4, 5

Pharmacokinetic Considerations in Young Infants

Infants 1-3 months of age demonstrate 3.6 times higher systemic exposure to montelukast compared to older infants (3-24 months) 6

While your 10-month-old patient is older than this studied cohort, this finding emphasizes the importance of age-appropriate dosing 6
The 4-mg dose has been specifically validated for safety in infants 6-23 months of age 1, 7

Safety Profile in Young Children

Montelukast has been evaluated for safety in 175 pediatric patients 6-23 months of age and was generally well tolerated 1

Common adverse events (≥2% frequency, more than placebo) in this age group include: 1

Upper respiratory infection
Wheezing
Otitis media
Pharyngitis, tonsillitis
Cough
Rhinitis

The frequency of less common adverse events was comparable between montelukast and placebo 1

Clinical Decision Algorithm

For a 10-month-old infant:

If the indication is perennial allergic rhinitis:
- Montelukast 4-mg oral granules once daily is FDA-approved 1
- First discuss neuropsychiatric risks with parents 4, 5
- Consider whether intranasal corticosteroids would be safer and more effective 4, 5
If the indication is asthma:
- Do NOT prescribe montelukast - it is not FDA-approved for asthma in children <12 months 1
- Consider alternative therapies appropriate for this age group 1
If the indication is off-label (e.g., bronchiolitis):
- Recognize this is not an FDA-approved indication 6
- The risk-benefit ratio is unfavorable given the FDA black box warning and availability of alternative therapies 4, 5

Critical Pitfalls to Avoid

Do not prescribe montelukast for asthma in infants <12 months of age - this is outside FDA approval 1
Do not prescribe for mild disease when safer alternatives are available 4, 5
Do not fail to counsel parents about neuropsychiatric risks before initiating therapy 4, 5
Do not use doses other than 4-mg oral granules in this age group 1, 2

Is montelukast (Singulair) safe for use in a 10-month-old infant?

Help us tailor your experience